Skip to main content
Erschienen in: World Journal of Surgery 11/2012

01.11.2012

Development of a Formula to Predict Parathyroid Carcinoma in Patients with Primary Hyperparathyroidism

verfasst von: Elias Karakas, Hans-Helge Müller, Vladimir K. Lyadov, Stephanie Luz, Ralph Schneider, Matthias Rothmund, Detlef K. Bartsch, Katja Schlosser

Erschienen in: World Journal of Surgery | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Cure of parathyroid carcinoma (PC) requires initial en bloc resection, including resection of all tumor-bearing tissue, with hemithyroidectomy and dissection of the central lymph node compartment. Unfortunately, no reliable preoperative criteria have yet been assessed to indicate a high likelihood of PC. Thus, the aim of the present study was to develop a formula to indicate preoperatively the presence of PC.

Methods

A prospective database of 1,363 patients with primary hyperparathyroidism (pHPT) was screened for patients with PC. Age, gender, surgical procedures, laboratory data, and follow-up results were evaluated and compared to a group of patients with benign pHPT. Based on preoperative serum calcium (Ca) and parathyroid hormone (PTH) levels, as well as patients’ age at the time of diagnosis, a formula was developed by a multivariate logistic model that estimates the individual risk for PC.

Results

Between 1987 and 2008, 19 patients with PC were identified. Ca (3.8 ± 0.3 vs 2.9 ± 0.3 mmo/l; p = 0.0002) and PTH levels (1,250 ± 769 vs 194 ± 204 pg/ml; p = 0.0030) were significantly higher in patients with PC than in those with benign pHPT. Patients with PC were also significantly younger than patients with benign pHPT (48.9 ± 12.1 vs 59.1 ± 13.8 years; p < 0.05). With a ≥5 % probability that a given patient suffered from PC, the sensitivity and specificity to identify the disease were 100 and 30 %, respectively, with the new Ca, PTH, and age based logarithmic formula.

Conclusions

The new logarithmic formula can be used to calculate the individual risk for PC. If the calculated individual risk exceeds 5 %, en bloc resection seems to be justified to provide long-term cure in case of PC.
Literatur
1.
Zurück zum Zitat Wang C, Gaz RD (1985) Natural history of parathyroid carcinoma. Diagnosis, treatment and results. Am J Surg 149:522–527PubMedCrossRef Wang C, Gaz RD (1985) Natural history of parathyroid carcinoma. Diagnosis, treatment and results. Am J Surg 149:522–527PubMedCrossRef
3.
4.
Zurück zum Zitat Holmes EC, Morton DL, Ketcham AS (1969) Parathyroid carcinoma: a collective review. Ann Surg 169:631–640PubMedCrossRef Holmes EC, Morton DL, Ketcham AS (1969) Parathyroid carcinoma: a collective review. Ann Surg 169:631–640PubMedCrossRef
5.
Zurück zum Zitat Wynne AG, van Heerden J, Carney JA et al (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 71:197–205PubMedCrossRef Wynne AG, van Heerden J, Carney JA et al (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 71:197–205PubMedCrossRef
6.
Zurück zum Zitat Bartsch DK, Reimund KP, Hasse C et al (1993) Das Nebenschielddrüsencarcinom. Problematik der Diagnosestellung und Therapie. Chirurg 64:114–121PubMed Bartsch DK, Reimund KP, Hasse C et al (1993) Das Nebenschielddrüsencarcinom. Problematik der Diagnosestellung und Therapie. Chirurg 64:114–121PubMed
7.
Zurück zum Zitat Kebebew E, Arici C, Duh Q-Y et al (2001) Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878–885PubMedCrossRef Kebebew E, Arici C, Duh Q-Y et al (2001) Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878–885PubMedCrossRef
8.
Zurück zum Zitat Hundahl SA, Fleming ID, Fremden AM et al (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a national cancer data base report. Cancer 86:538–544PubMedCrossRef Hundahl SA, Fleming ID, Fremden AM et al (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a national cancer data base report. Cancer 86:538–544PubMedCrossRef
9.
Zurück zum Zitat Hamill J, Maoate K, Beasley SW et al (2002) Familial parathyroid carcinoma in a child. J Paediatr Child Health 38:314–317PubMedCrossRef Hamill J, Maoate K, Beasley SW et al (2002) Familial parathyroid carcinoma in a child. J Paediatr Child Health 38:314–317PubMedCrossRef
10.
Zurück zum Zitat Pelizzo MR, Piotto A, Bergamasco A et al (2001) Parathyroid carcinoma. Therapeutic strategies, derived from 20 years of experience. Minerva Endocrinol 26:23–29PubMed Pelizzo MR, Piotto A, Bergamasco A et al (2001) Parathyroid carcinoma. Therapeutic strategies, derived from 20 years of experience. Minerva Endocrinol 26:23–29PubMed
11.
Zurück zum Zitat Anderson BJ, Samaan NA, Vassilopoulou-Sellin R et al (1983) Parathyroid carcinoma; features and difficulties in diagnosis and treatment. Surgery 94:906–915PubMed Anderson BJ, Samaan NA, Vassilopoulou-Sellin R et al (1983) Parathyroid carcinoma; features and difficulties in diagnosis and treatment. Surgery 94:906–915PubMed
12.
Zurück zum Zitat Klink BK, Karulf RE, Maimon WN et al (1991) Nonfunctioning parathyroid carcinoma. Am Surg 57:463–467PubMed Klink BK, Karulf RE, Maimon WN et al (1991) Nonfunctioning parathyroid carcinoma. Am Surg 57:463–467PubMed
13.
Zurück zum Zitat Schantz A, Castleman B (1973) Parathyroid carcinoma. A study of 70 cases. Cancer 31:600–605PubMedCrossRef Schantz A, Castleman B (1973) Parathyroid carcinoma. A study of 70 cases. Cancer 31:600–605PubMedCrossRef
14.
Zurück zum Zitat Tan MH, Morrison C, Wang P et al (2004) The BT loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10:6629–6637PubMedCrossRef Tan MH, Morrison C, Wang P et al (2004) The BT loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10:6629–6637PubMedCrossRef
15.
Zurück zum Zitat Juhlin CC, Nilsson I-L, Johansson K et al (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21:166–177PubMedCrossRef Juhlin CC, Nilsson I-L, Johansson K et al (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21:166–177PubMedCrossRef
16.
Zurück zum Zitat Robert JH, Trombetti A, Garcia A et al (2005) Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of literature. Ann Surg Oncol 12:1–7CrossRef Robert JH, Trombetti A, Garcia A et al (2005) Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of literature. Ann Surg Oncol 12:1–7CrossRef
17.
Zurück zum Zitat Fujimoto Y, Obara T, Ito Y et al (1984) Surgical treatment of ten cases of parathyroid carcinoma: importance of an initial en bloc tumor resection. World J Surg 8:392–400PubMedCrossRef Fujimoto Y, Obara T, Ito Y et al (1984) Surgical treatment of ten cases of parathyroid carcinoma: importance of an initial en bloc tumor resection. World J Surg 8:392–400PubMedCrossRef
19.
20.
Zurück zum Zitat Busaidy NL, Jimenez C, Habra MA et al (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26:716–726PubMedCrossRef Busaidy NL, Jimenez C, Habra MA et al (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26:716–726PubMedCrossRef
22.
Zurück zum Zitat Sandelin K, Thompson NW, Bondeson L (1991) Metastatic parathyroid carcinoma: dilemmas in management. Surgery 110:978–988PubMed Sandelin K, Thompson NW, Bondeson L (1991) Metastatic parathyroid carcinoma: dilemmas in management. Surgery 110:978–988PubMed
23.
Zurück zum Zitat Hundley JC, Albertson DA, Bradley RF et al (2003) Resection of a pulmonary metastasis from parathyroid carcinoma. Am Surg 69:779–783PubMed Hundley JC, Albertson DA, Bradley RF et al (2003) Resection of a pulmonary metastasis from parathyroid carcinoma. Am Surg 69:779–783PubMed
24.
Zurück zum Zitat Levin KE, Galante M, Clark OH (1987) Parathyroid carcinoma vs parathyroid adenoma in patients with profound hypercalcemia. Surgery 101:647–660 Levin KE, Galante M, Clark OH (1987) Parathyroid carcinoma vs parathyroid adenoma in patients with profound hypercalcemia. Surgery 101:647–660
25.
Zurück zum Zitat Ippolito G, Palazzo FF, Sebag F et al (2007) Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 94:566–570PubMedCrossRef Ippolito G, Palazzo FF, Sebag F et al (2007) Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 94:566–570PubMedCrossRef
26.
Zurück zum Zitat Blyth C, Still H (1983) Binominal confidence intervals. J Am Stat Assoc 78:108–116CrossRef Blyth C, Still H (1983) Binominal confidence intervals. J Am Stat Assoc 78:108–116CrossRef
27.
Zurück zum Zitat Casella G (1986) Refining binominal confidence intervals. Can J Stat 14:113–129CrossRef Casella G (1986) Refining binominal confidence intervals. Can J Stat 14:113–129CrossRef
28.
Zurück zum Zitat Zielke A, Rothmund M (2007) Praxis der Viszeralchirurgie, Endokrine Chirurgie. Band 1 2. Auflage. Springer, Heidelberg, p 119–122 (in German) Zielke A, Rothmund M (2007) Praxis der Viszeralchirurgie, Endokrine Chirurgie. Band 1 2. Auflage. Springer, Heidelberg, p 119–122 (in German)
29.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803PubMedCrossRef Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803PubMedCrossRef
30.
Zurück zum Zitat Chiang F-Y, Wang L-F, Huang Y-F et al (2005) Recurrent laryngeal nerve palsy after thyroidectomy with routine identification of the recurrent laryngeal nerve. Surgery 137:2–347CrossRef Chiang F-Y, Wang L-F, Huang Y-F et al (2005) Recurrent laryngeal nerve palsy after thyroidectomy with routine identification of the recurrent laryngeal nerve. Surgery 137:2–347CrossRef
31.
Zurück zum Zitat Erbil Y, Barbaros U, İşsever H et al (2007) Predictive factors for recurrent laryngeal nerve palsy and hypoparathyroidism after thyroid surgery. Clin Otolaryngol 32:32–37PubMedCrossRef Erbil Y, Barbaros U, İşsever H et al (2007) Predictive factors for recurrent laryngeal nerve palsy and hypoparathyroidism after thyroid surgery. Clin Otolaryngol 32:32–37PubMedCrossRef
32.
Zurück zum Zitat Lee PK, Jarosek SL, Virnig BA et al (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109:1736–1741PubMedCrossRef Lee PK, Jarosek SL, Virnig BA et al (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109:1736–1741PubMedCrossRef
33.
Zurück zum Zitat Chahinian AP, Holland JF, Nieburgs HE et al (1981) Metastatic non-functioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am J Med Sci 282:80–84PubMedCrossRef Chahinian AP, Holland JF, Nieburgs HE et al (1981) Metastatic non-functioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am J Med Sci 282:80–84PubMedCrossRef
34.
Zurück zum Zitat Calandra DB, Cheifec G, Foy BK et al (1984) Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 96:1132–1135PubMed Calandra DB, Cheifec G, Foy BK et al (1984) Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 96:1132–1135PubMed
35.
Zurück zum Zitat Munson ND, Foote RL, Northcutt RC et al (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98:2378–2384PubMedCrossRef Munson ND, Foote RL, Northcutt RC et al (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98:2378–2384PubMedCrossRef
36.
Zurück zum Zitat Bradwell AR, Harvey TC (1999) Control of hypercalcemia of parathyroid carcinoma by immunization. Lancet 353(9150):370–373PubMedCrossRef Bradwell AR, Harvey TC (1999) Control of hypercalcemia of parathyroid carcinoma by immunization. Lancet 353(9150):370–373PubMedCrossRef
37.
Zurück zum Zitat Betey D, Bradwell AR, Harvey TC et al (2004) Hormonal and biochemical normalization and tumour shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413–3420CrossRef Betey D, Bradwell AR, Harvey TC et al (2004) Hormonal and biochemical normalization and tumour shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413–3420CrossRef
38.
Zurück zum Zitat Schott M, Feldkamp J, Schattenberg D et al (2000) Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300–306PubMedCrossRef Schott M, Feldkamp J, Schattenberg D et al (2000) Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300–306PubMedCrossRef
39.
Zurück zum Zitat Shane E (2001) Clinical review 122: parathyroid carcinoma. J Clin Endocrin Metab 86:485–493CrossRef Shane E (2001) Clinical review 122: parathyroid carcinoma. J Clin Endocrin Metab 86:485–493CrossRef
40.
Zurück zum Zitat Dotzenrath C, Goretzki PE, Sarbia M et al (2001) Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol 27:383–389PubMedCrossRef Dotzenrath C, Goretzki PE, Sarbia M et al (2001) Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol 27:383–389PubMedCrossRef
Metadaten
Titel
Development of a Formula to Predict Parathyroid Carcinoma in Patients with Primary Hyperparathyroidism
verfasst von
Elias Karakas
Hans-Helge Müller
Vladimir K. Lyadov
Stephanie Luz
Ralph Schneider
Matthias Rothmund
Detlef K. Bartsch
Katja Schlosser
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 11/2012
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-012-1707-9

Weitere Artikel der Ausgabe 11/2012

World Journal of Surgery 11/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.